Latest Conference Articles

When administering T-cell–modifying therapies, infections during and after treatment are a serious and pertinent risk.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.

A digital therapeutic app enhances access to behavioral cough suppression therapy.

Infectious disease experts provide the latest updates in RSV, pneumococcal disease, whooping cough, and multidrug-resistant tuberculosis.

New research reveals how menopausal hormone therapy impacts cognitive health in postmenopausal women, highlighting the importance of administration routes and estrogen types.

Experts outline innovative approaches to reduce inequities in diagnostic access and optimize patient outcomes.

James Chalmers, MBChB, PhD, discusses the ASPEN trial's findings on brensocatib's impact on lung structure and function in bronchiectasis patients.

A recent study reveals imlunestrant plus abemaciclib shows superior efficacy over fulvestrant plus abemaciclib in treating advanced ER+, HER2- breast cancer.

Megan Dulohery Scrodin, MD, discusses COPD management challenges and the need for accessible care and cost reduction.

Elinzanetant was effective in women with low vasomotor symptom (VMS) burden and those with endocrine therapy-caused VMS.

Compared with late postmenopausal women, menopausal hormone therapy (MHT) may influence certain Alzheimer disease-related biomarkers in early postmenopausal women.

Subcutaneous amivantamab demonstrated robust activity in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with checkpoint inhibitors and platinum chemotherapy.

The combination significantly improved event-free and overall survival compared with surgery alone, marking the first study to show an overall survival benefit in this patient population.

The phase 3 trial demonstrated significant improvements in overall and progression-free survival, reinforcing the combination as a standard-of-care option across MMR subgroups.

Sara Assaf, MD, shares insights on selecting biologic therapies for severe asthma, including biomarkers, patient factors, and managing nonresponders effectively.

The FDA's approval of GLP-1 for obstructive sleep apnea enhances treatment options, emphasizing pharmacists' vital role in patient care and management.

New findings reveal the Ki-67 index's crucial role in predicting breast cancer recurrence post-chemotherapy, while abemaciclib benefits all patient subgroups.

Increasing vaccine confidence demands that pharmacists move beyond simply sharing facts to utilizing effective communication strategies.

Olomorasib shows promising intracranial efficacy in treating KRAS G12C-mutant NSCLC with brain metastases, highlighting a potential shift in treatment strategies.

Long-term findings from the REASSURE study confirm Radium-223’s acceptable hematologic safety profile and reinforce the importance of early use alongside bone-protecting agents to minimize fracture risk and optimize outcomes.

Balazs Halmos, MD, discusses how the COPERNICUS trial aims to build on previous amivantamab studies.

In the ARANOTE trial, darolutamide combined with ADT significantly delayed disease progression and maintained quality of life for patients with metastatic hormone-sensitive prostate cancer, supporting its use as a chemotherapy-free option.

Personalized cancer vaccines target tumor heterogeneity, enhancing immune responses and improving treatment outcomes in diverse cancer types.

Experts at ESMO 2025 highlight antibody-drug conjugates in HER2-positive metastatic breast cancer treatment.

Emerging biomarkers and targeted therapies are reshaping the landscape of lung cancer treatment and drug development.

Nicoletta Colombo, MD, PhD, discusses why metronomic chemotherapy dosing and careful regimen design may have driven the success of the KEYNOTE-B96 trial.

Datopotamab deruxtecan-dlnk improved duration of response by roughly 5 months compared with chemotherapy in first-line mTNBC.